ACLX · Arcellx, Inc.
$115.07
+0.00 (+0.00%)
At close · Apr 29
Market Cap
$6.73B
Shares
58.48M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$22.29M
-79.4%
FY2025
Net Income
-$228.93M
-113.3%
FY2025
Operating Margin
-1135.61%
-1008.2pp
FY2025
Diluted EPS
-$4.07
-103.5%
FY2025
Operating Cash Flow
-$210.26M
-151.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| $22.29M | $107.94M | $110.32M | — | — | |
| $157.61M | $157.09M | $133.85M | $149.56M | $46.88M | |
| $117.76M | $88.41M | $66.35M | $41.7M | $18.14M | |
| $6.68M | $5.19M | $2.04M | $1.32M | $1.04M | |
| $275.37M | $245.51M | $200.2M | $191.26M | $65.02M | |
| -$253.08M | -$137.57M | -$89.88M | -$191.26M | -$65.02M | |
| -1135.61% | -127.46% | -81.47% | — | — | |
| -$246.41M | -$132.38M | -$87.84M | -$189.94M | -$63.98M | |
| $24.22M | $32.29M | $19.85M | $2.58M | $49K | |
| -$228.87M | -$105.28M | -$70.03M | -$188.68M | — | |
| $69K | $2.07M | $663K | $0 | $0 | |
| -$228.93M | -$107.35M | -$70.69M | -$188.68M | -$64.97M | |
| -1027.25% | -99.46% | -64.08% | — | — | |
| -$228.94M | -$107.05M | -$69.92M | -$188.88M | -$64.99M | |
| USD/shares | -$4.07 | -$2.00 | -$1.47 | -$5.19 | -$145.55 |
| USD/shares | -$4.07 | -$2.00 | -$1.47 | -$5.19 | -$145.55 |
| shares | 56.31M | 53.57M | 48.06M | 36.36M | 446.38K |
| shares | 56.31M | 53.57M | 48.06M | 36.36M | 446.38K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 8.41×
EV/EBIT
—
Peer median 24.58×
P/E (TTM)
—
Peer median 18.96×
Peer medians compare against the 169 similar-size Biotechnology companies (of 521 listed).